|
html xmlns=http://www.w3.org/1999/xhtmlbody
table border= trtd
pSpexis AG / Key words: Miscellaneousbr/
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license...
Lire...
html xmlns=http://www.w3.org/1999/xhtmlbody
table border= trtd
pKinarus Therapeutics Holding AG / Key words: Annual Results/Capital Increasebr/
Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with...
Lire...
html xmlns=http://www.w3.org/1999/xhtmlbody
table border= trtd
pR&S Group Holding AG / Key words: Annual Results/Annual Resultsbr/
R&S Group publishes annual report 2023 with strong sales and record profitability and confirms good start into 2024 with high cash...
Lire...
17/04/2024 07:01
UCB Media Room: FINTEPLA®▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with LGS
...
Lire...
17/04/2024 07:00
EQS-News: HomeToGo Announces Results of Public Share Tender Offer
html xmlns=http://www.w3.org/1999/xhtmlbody
table border= trtd
p
EQSNews: HomeToGo SE
/ Key words: Share Buyback
br/
HomeToGo Announces Results of Public Share Tender Offer br/br/
17.04.2024 / 07:00 CET/CESTbr/
The issuer is solely...
Lire...
17/04/2024 07:00
EQS-News: R. STAHL, with significantly improved sales and profitability in 2023, forecasts further sales growth for 2024
html xmlns=http://www.w3.org/1999/xhtmlbody
table border= trtd
p
EQSNews: R. Stahl AG
/ Key words: Annual Report/Annual Results
br/
R. STAHL, with significantly improved sales and profitability in 2023, forecasts further sales growth for 2024...
Lire...
html xmlns=http://www.w3.org/1999/xhtmlbody
table border= trtd
p
EQSNews: HELLA GmbH & Co. KGaA
/ Key words: Quarterly / Interim Statement/Development of Sales
br/
FORVIA HELLA starts fiscal year 2024 with slight sales growth...
Lire...
17/04/2024 07:00
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Press Release
New 48week frexalimab phase 2 data support potential for
high sustained efficacy in multiple sclerosis
Data support frexalimab as a potential firstinclass, highefficacy, nonlymphocyte
depleting...
Lire...
17/04/2024 07:00
Onramp MENA: Bitcoin Asset Management in the MENA Region
pistrongExpanding Horizons with Onramp MENA/strong/i/ppstrongDUBAI, UAE / ACCESSWIRE / April 17, 2024 / /strongIn a world where financial innovation meets tradition, Onramp MENA stands at the forefront, marking a new chapter in bitcoin asset management tailored for the Middle East and North Africa...
Lire...
|